• O.Graciela Scharovsky National University of Rosario
  • Leandro E. Mainetti
  • Viviana R. Rozados


The introduction of the maximum tolerated dose in usual treatment protocols, and its concomitant overt toxicity, made it necessary to impose rest periods between cycles of therapy which, not only involve re-growth of tumor cells but also growth of the selected clones resistant to the therapy. In order to avoid the problems caused by the traditional chemotherapeutic regimens it was proposed a new modality of drug administration named metronomic chemotherapy. Such a denomination makes reference to a chronic, equally spaced administration of, generally, low doses of different chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality relays not only in its antitumor efficacy with very low toxicity, but also in a cell target switch, now aiming to the tumor endothelial cells. The knowledge acquired in the experimental field in metronomic chemotherapy plus the increasing experience that is being obtained in the clinical setting will help to lead a change in the design of therapeutic protocols against cancer.

Author Biography

O.Graciela Scharovsky, National University of Rosario
Head of Experimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, Natonal University of Rosario
How to Cite
Scharovsky, O., Mainetti, L. E., & Rozados, V. R. (1). METRONOMIC CHEMOTHERAPY: CHANGING THE PARADIGM THAT MORE IS BETTER. Current Oncology, 16(2), 7-15.
Medical Oncology